FIGURE 3.

BAK/BAX are required for ceramide generation following cisplatin treatment. Wild-type (WT) and Bak^−/− Bax^−/− (DKO) BMK cells were treated with vehicle (water) or cisplatin. a, viability; b, caspase 3/7 activity, and long-chain ceramide measurements in WT (c) and DKO (d) cells were performed as described in Fig. 1. c, where indicated WT BMK cells were preincubated (2 h) with myriocin (100 nm) prior to being treated with cisplatin. The average of three independent experiments is shown. Error bars, ±S.D. For statistical analyses a two-way ANOVA was performed with a Bonferroni post-test. *, p ≤ 0.05 statistically significant difference between treatment and its corresponding control and #, p ≤ 0.05 statistically significant difference between WT and the time-matched myr and DKO value.